Biomarkers for severe COVID-19 - EBioMedicine

Biomarkers for severe COVID-19 - EBioMedicine

A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research - EBioMedicine

A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research - EBioMedicine

Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study - The Lancet Rheumatology

Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study - The Lancet Rheumatology

Defining COVID-19-associated hyperinflammatory syndrome in specific populations - The Lancet Rheumatology

Defining COVID-19-associated hyperinflammatory syndrome in specific populations - The Lancet Rheumatology

Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study - The Lancet Rheumatology

Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study - The Lancet Rheumatology

Repurposing drugs for treatment of COVID-19 - The Lancet Respiratory Medicine

Repurposing drugs for treatment of COVID-19 - The Lancet Respiratory Medicine

Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? - The Lancet Respiratory Medicine

Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? - The Lancet Respiratory Medicine